Cardiovascular effects of donepezil in patients with dementia

Dementia and Geriatric Cognitive Disorders

Volumn 15, Issue 4, 2003, Pages 183-188

  McLaren, A T ^a,c   Allen, J ^b   Murray, A ^b   Ballard, C G ^a   Kenny, R A ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b FREEMAN HOSPITAL   (United Kingdom)

^c NEWCASTLE GENERAL HOSPITAL   (United Kingdom)

Author keywords

Autonomic nervous system; Cholinesterase inhibitors; Donepezil; Falls; Heart rate variability; Power spectral analysis; Syncope

Indexed keywords

DONEPEZIL;

AGED; ALZHEIMER DISEASE; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR EFFECT; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DATA ANALYSIS; FEMALE; FREQUENCY MODULATION; HEART RATE VARIABILITY; HUMAN; LEWY BODY; MALE; PATIENT COMPLIANCE; PILOT STUDY; POWER SPECTRUM; PRIORITY JOURNAL; RR INTERVAL; SIDE EFFECT; SPECTROSCOPY;

AGED; AUTONOMIC NERVOUS SYSTEM; CARDIOVASCULAR SYSTEM; CHOLINESTERASE INHIBITORS; DEMENTIA; FEMALE; HEART RATE; HUMANS; INDANS; MALE; PILOT PROJECTS; PIPERIDINES; REGRESSION ANALYSIS; SAMPLING STUDIES; SYNCOPE;

EID: 0346319008     PISSN: 14208008     EISSN: None     Source Type: Journal    
DOI: 10.1159/000068781     Document Type: Article

References (37)

1. Malliani A, Pagani M, Lombardi F, Cerutti S: Cardiovascular neural regulation explored in the frequency domain. Circulation 1991;84:482-492.
2. Freeman R, Saul JP, Roberts MS, Berger RD, Broadbridge C, Cohen RJ: Spectral analysis of heart rate in diabetic autonomic neuropathy. A comparison with standard tests of autonomic function. Arch Neurol 1991;48:185-190.
3. Howorka K, Pumprla J, Schabmann A: Optimal parameters of short-term heart rate spectrogram for routine evaluation of diabetic cardiovascular autonomic neuropathy. J Auton Nerv Syst 1998;69:164-172.
4. Bellavere F, Balzani I, de Masi G, Carraro M, Carenza P, Cobelli C, Thomaseth K: Power spectral analysis of heart-rate variations improves assessment of diabetic autonomic neuropathy. Diabetes 1992;41:633-640.
5. Kleiger RE, Miller JP, Bigger JT Jr, Moss AJ: Decreased heart rate variability and its association with increased mortality after acute myocardial infarction. Am J Cardiol 1987;59:256-262.
6. Bigger JT Jr, Fleiss JL, Steinman RC, Rolnitzky LM, Kleiger RE, Rottman JN: Frequency domain measures of heart period variability and mortality after myocardial infarction. Circulation 1992;85:164-171.
7. McIntosh SJ, Lawson J, Kenny RA: Clinical characteristics of vasodepressor, cardioinhibitory, and mixed carotid sinus syndrome in the elderly. Am J Med 1993;95:203-208.
8. Richardson DA, Bexton RS, Shaw FE, Kenny RA: Prevalence of cardioinhibitory carotid sinus hypersensitivity in patients 50 years or over presenting to the accident and emergency department with 'unexplained' or 'recurrent' falls. Pacing Clin Electrophysiol 1997;20:820-823.
9. Ballard CG, Shaw F, Lowery K, McKeith I, Kenny R: The prevalence, assessment and associations of falls in dementia with Lewy bodies and Alzheimer's disease. Dement Geriatr Cogn Disord 1999;10:97-103.
10. Ballard C, Shaw F, McKeith I, Kenny R: High prevalence of neurovascular instability in neurodegenerative dementia's. Neurology 1998;51:1760-1762.
11. Perry EK, Tomlinson BE, Blessed G, Bergmann K, Gibson PH, Perry RH: Correlation of cholinergic abnormalities with senile plaques and mental test scores in senile dementia. BMJ 1978;2:1457-1459.
12. Whitehouse PJ, Price DL, Struble RG, Clark AW, Coyle JT, Delon MR: Alzheimer's disease and senile dementia: Loss of neurons in the basal forebrain. Science 1982;215:1237-1239.
13. Rogers SL, Doody RS, Mohs RC, Friedhoff LT: Donepezil improves cognition and global function in Alzheimer disease: A 15-week, double-blind, placebo-controlled study. Donepezil Study Group. Arch Int Med 1998;158:1021-1031.
14. Rogers SL, Farlow MR, Doody RS, Mohs R, Friedhoff LT: A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Donepezil Study Group. Neurology 1998;50:136-145.
15. Burns A, Rossor M, Hecker J, Gauthier S, Petit H, Moller HJ, Rogers SL, Friedhoff LT: The effects of donepezil in Alzheimer's disease - Results from a multinational trial. Dementia Geriatr Cogn Disord 1999;10:237-244.
16. Rosler M, Anand R, Cicin-Sain A, Gauthier S, Agid Y, Dal-Bianco P, Stahelin HB, Hartman R, Gharabawi M: Efficacy and safety of rivas-tigmine in patients with Alzheimer's disease: International randomised controlled trial. BMJ 1999;318:633-638.
17. National Institute for Clinical Excellence: Guidance on the Use of Donepezil, Rivastigmine and Galantamine for the treatment of Alzheimer's Disease. Technology Appraisal Guidance 2001;19.
18. Nordberg A, Svensson AL: Cholinesterase inhibitors in the treatment of Alzheimer's disease: A comparison of tolerability and pharmacology. Drug Saf 1998;19:465-480.
19. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM: Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA Work Group under the auspices of the Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984;34:949-944.
20. McKeith IG, Galasko D, Kosaka K, Perry EK, Dickson DW, Hansen LA, Salmon DP, Lowe J, Mirra SS, Byrne EJ, Lennox G, Quinn NP, Edwardson JA, Ince PG, Bergeron C, Burns A, Miller BL, Lovestone S, Collerton D, Jansen EN, Ballard C, de Vos RA, Wilcock GK, Jellinger KA, Perry RH: Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): Report of the consortium on DLB international workshop. Neurology 1996;47:1113-1124.
21. McKeith IG, Ballard CG, Perry RH, Ince PG, O'Brien JT, Neill D, Lowery K, Jaros E, Barber R, Thompson P, Swann A, Fairbrain AF, Perry EK: Prospective validation of consensus criteria for the diagnosis of dementia with Lewy bodies. Neurology 2000;54:1050-1058.
22. Lord SW, Senior RR, Das M, Whittam AM, Murray A, McComb JM: Low-frequency heart rate variability: Reproducibility in cardiac transplant recipients and normal subjects. Clin Sci 2001;100:43-46.
23. Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology: Heart rate variability. Standards of measurement, physiological interpretation and clinical use. Circulation 1996;93:1043-1065.
24. Anonymous: Consensus statement on the definition of orthostatic hypotension, pure autonomic failure, and multiple system atrophy. J Neurol Sci 1996;144:218-219.
25. Brezenoff HE, Giuliano R: Cardiovascular control by cholinergic mechanisms in the central nervous system. Annu Rev Pharmacol Toxicol 1982;22:341-381.
26. Buccafusco JJ: The role of central cholinergic neurons in the regulation of blood pressure and in experimental hypertension. Pharmacol Rev 1996;48:179-211.
27. Savci V, Gurun MS, Cavun S, Ulus IH: Cardiovascular effects of centrally injected tetrahydroaminoacridine in conscious normotensive rats. Eur J Pharmacol 1998;346:35-41.
28. Allal C, Lazartigues E, Tran MA, Brefel-Courbon C, Gharib C, Montastruc JL, Rascol O: Central cardiovascular effects of tacrine in the conscious dog: A role for catecholamines and vasopressin release. Eur J Pharmacol 1998;348:191-198.
29. Lazartigues E, Freslon JL, Tellioglu T, Brefel-Courbon C, Pelat M, Tran MA, Montastruc JL, Rascol O: Pressor and bradycardic effects of tacrine and other acetylcholinesterase inhibitors in the rat. Eur J Pharmacol 1998;361:61-71.
30. Medina A, Bodick N, Goldberger AL, Mac Mahon M, Lipsitz LA: Effects of central muscarinic-1 receptor stimulation on blood pressure regulation. Hypertension 1997;29:828-834.
31. Ally A, Wilson LB, Nobrega AC, Mitchell JH: Cardiovascular effects elicited by central administration of physostigmine via M2 muscarinic receptors in conscious cats. Brain Res 1995;677:268-276.
32. Nobrega AC, Carvalho AC, Santos KB, Soares PP: Cholinergic stimulation with pyridostigmine blunts the cardiac responses to mental stress. Clin Auton Res 1999;9:11-16.
33. Anonymous: Aricept datasheet; in Datapharm: ABPI Compendium of Data Sheets. London, Datapharm Publications, 1999, pp 375-376.
34. Corey-Bloom J, Anand R, Veach J: A randomized trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartrate), a new acetyl-cholinesterase inhibitor, in patients with mild to moderately severe Alzheimer's disease. Int J Geriatr Psychopharmacol 1998;1:55-65.
35. Cummings JL, Cyrus PA, Bieber F, Mas J, Ora-zem J, Gulanski B: Metrifonate treatment of the cognitive deficits of Alzheimer's disease. Neurology 1998;50:1214-1221.
36. Pomara N, Deptula D, Singh R: Pretreatment postural blood pressure drop as a possible predictor of response to the cholinesterase inhibitor velnacrine (HP 029) in Alzheimer's disease. Psychopharmacol Bull 1991;27:301-307.
37. Karemaker JM: Heart rate variability: Why do spectral analysis? Heart 1997;77:99-101.